All In Biotech

Drug Trial Radar · NCT05256732

Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

Phase 1, Multiple Dose, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AT-527 Following Oral Administration Under Fasting Conditions or With a Meal in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Oct 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Feb 22, 2022

Primary completion

Aug 23, 2022

Study completion Aug 23, 2022

Sponsor

Lead sponsor
Atea Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 following oral administration under fasting conditions or with a meal in healthy adult subjects

Conditions

  • Healthy Volunteer Study

Interventions

  • AT-527 fastedDrug

    AT-527 administered twice daily (BID) for 5 days fasted

  • Placebo Comparator fastedOther

    Matching placebo administered twice daily (BID) for 5 days fasted

  • AT-527 fedDrug

    AT-527 administered twice daily (BID) for 5 days fed

  • Placebo Comparator fedOther

    Matching placebo administered twice daily (BID) for 5 days fed

  • AT-527Drug

    AT-527 administered twice daily (BID)

  • AT-527 single doseDrug

    AT-527 single dose fasted/fed cross-over

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) of AT-527Time frame: Day 1
  2. Pharmacokinetics (PK) of AT-527Time frame: Day 1
  3. Pharmacokinetics (PK) of AT-527Time frame: Day 1
  4. Proportions of subjects experiencing treatment-emergent adverse eventsTime frame: Day 1-10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Atea Study Site

    Québec, Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.